Domestic First Generics: Qilu Pharmaceutical and Zhengda Tianqing's Pazopanib Tablets Approved Simultaneously for Renal Cell Carcinoma

On March 10, the official website of the National Medical Products Administration showed that pazopanib tablets developed by Qilu Pharmaceutical and CHIATAI TIANQING were both approved for marketing, with an indication for adjuvant treatment of renal cell carcinoma. These are the first two generic versions of pazopanib to be marketed in China.

Pazopanib, developed by GlaxoSmithKline, is a novel oral angiogenesis inhibitor that interferes with the formation of new blood vessels required for the survival and growth of refractory tumors. It targets vascular endothelial growth factor receptor (VEGFR) and acts by inhibiting the generation of new blood vessels that supply the tumor.

Molecular Structure of Pazopanib (Source: NextPharma Database by PharmaCube)

Pazopanib was first approved by the FDA for marketing in 2009. The currently approved indications include advanced renal cell carcinoma and soft tissue sarcoma (STS). In addition, several studies on the use of this drug for the treatment of ovarian cancer, non-small cell lung cancer, and osteosarcoma have entered Phase III.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position; if you need to reproduce it, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Medcube Reader Survey Questionnaire

Thank You for Your Support. We Look Forward to Your Feedback.

Scan the QR code to provide valuable suggestions